Did Rep. Chris Collins sell his biotech stock without telling Congress?

first_img Rep. Chris Collins, the New York lawmaker facing insider trading charges, was once the No. 2 shareholder in an Australian firm called Innate Immunotherapeutics. According to the company’s most recent disclosure, he’s no longer even in the top 20 shareholders.What’s unclear is what happened to his shares. National Biotech Reporter Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast. By Damian Garde Nov. 12, 2018 Reprints Rep. Chris Collins (R-N.Y.) Win McNamee/Getty Images Damian Garde What’s included? Politics Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More center_img What is it? Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints Tags biotechnologyCongressfinance [email protected] Did Rep. Chris Collins sell his biotech stock without telling Congress? @damiangarde GET STARTEDlast_img read more